Journal
NEUROSCIENCE LETTERS
Volume 801, Issue -, Pages -Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.neulet.2023.137159
Keywords
Alzheimer?s disease; Bone morphogenetic protein 9; Low-density lipoprotein receptor-related pro-tein 1; Amyloid beta; Neuroinflammation
Categories
Ask authors/readers for more resources
Our previous study showed that bone morphogenetic protein 9 (BMP9) can improve amyloid pathology and cognitive impairments in APP/PS1 mice. This study found that BMP9 significantly increased the expression of low-density lipoprotein receptor-related protein 1 (LRP1) in the brains of APP/PS1 mice. Silencing LRP1 promoted amyloid plaque accumulation and neuroinflammation, and impaired learning and memory functions in BMP9-treated APP/PS1 mice.
Alzheimer's disease (AD) is the most common cause of dementia worldwide. Our previous study revealed that bone morphogenetic protein 9 (BMP9) could ameliorate the amyloid pathology and cognitive impairments in a transgenic model of AD. However, the mechanisms underlying the protective effect of BMP9 against amyloid pathology remain unknown. Low-density lipoprotein receptor-related protein 1 (LRP1) plays an essential role in the clearance of amyloid beta. Here, we demonstrated that intranasal BMP9 significantly enhanced the expression of LRP1 in the brains of APP/PS1 mice. Importantly, silencing LRP1 significantly promoted the amyloid plaques accumulation and facilitated the neuroinflammation in the brains of BMP9-treated APP/PS1 mice. Furthermore, silencing LRP1 significantly impaired the learning and memory functions of BMP9-treated APP/PS1 mice. Our results suggest that BMP9 ameliorate the amyloid pathology and cognitive dysfunction in APP/PS1 mice by promoting the expression of LRP1.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available